Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)
This study is ongoing, but not recruiting participants.
Study NCT00642395 Information provided by University Hospital, Toulouse
First Received: March 13, 2008 Last Updated: March 24, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Multiple Myeloma
Additional conditions recognized in this trial
Neoplasms, Plasma Cell
More general conditions related to this trial
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Paraproteinemias
Vascular Diseases
Interventions listed in this trial
Bortezomib
Additional drug interventions recognized in this trial
Melphalan
More general drug interventions related to this trial
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Therapeutic Uses
Sponsors listed in this trial
University Hospital, Toulouse
Intergroupe Francophone du Myelome
Back to top of Main Content
